Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) announced that it is being acquired by Bristol-Myers Squibb (NYSE: BMY) in a deal that is worth roughly $5.3 billion.

• Do you own shares of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN)?

• Did you buy AMLN shares before July 2, 2012?

• Do you think that the proposed deal is unfair to Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) shareholders? Is $31 in cash too low for Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN)?

Think this deal is unfair? Call 1-800-934-2921 right now to protect your rights.

If you own any amount of AMLN shares, contact our law firm today to protect your rights.

Own shares of AMLN and don't like this deal with Bristol-Myers? Our law firm is investigating potential claims against the board of directors of AMLN concerning possible breaches of fiduciary duty and other violations of securities laws related to the agreement to be being purchased by Bristol-Myers Squibb (NYSE: BMY) in a deal that is worth roughly $5.3 billion.

Own AMLN stock?

If you are a shareholder of any amount of AMLN complete the form on this page or call Attorney Bill Kyros at 1-800-934-2921 to discuss your rights.

Kyros Law LLP is a Boston-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions.

Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialisation of drug candidates for the treatment of diabetes, obesity and other diseases.